Intertwining of activin a and TGFβ signaling: Dual roles in cancer progression and cancer cell invasion

Cancers

Volumn 7, Issue 1, 2014, Pages 70-91

  Loomans, Holli A ^a   Andl, Claudia D ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Activin A; Cancer; Cell adhesion; Cell migration; EMT; TGF

Indexed keywords

ACTIVIN A; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL REGENERATION; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM TUMOR; FIBROBLAST; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PLEIOTROPY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; WOUND HEALING;

EID: 84920921854     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7010070     Document Type: Review

References (151)

1. Brown, S.; Teo, A.; Pauklin, S.; Hannan, N.; Cho, C.H.-H.; Lim, B.; Vardy, L.; Dunn, N.R.; Trotter, M.; Pedersen, R.; et al. Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cells 2011, 29, 1176–1185h.
2. Faure, S.; Lee, M.A.; Keller, T.; ten Dijke, P.; Whitman, M. Endogenous patterns of TGFβ superfamily signaling during early Xenopus development. Development 2000, 127, 2917–2931.
3. Matzuk, M.M.; Finegold, M.J.; Su, J.-G.J.; Hsueh, A.J.; Bradley, A. α-Inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 1992, 360, 313–319.
4. Dale, L.; Jones, C.M. BMP signalling in early Xenopus development. Bioessays 1999, 21, 751–760.
5. Jones, K.L.; de Kretser, D.M.; Patella, S.; Phillips, D.J. Activin A and follistatin in systemic inflammation. Mol. Cell. Endocrinol. 2004, 225, 119–125.
6. Kwon, S.J.; Lee, G.T.; Lee, J.-H.; Iwakura, Y.; Kim, W.-J.; Kim, I.Y. Mechanism of pro-tumorigenic effect of BMP-6: Neovascularization involving tumor-associated macrophages and IL-1α. Prostate 2014, 74, 121–133.
7. Burdette, J.E.; Jeruss, J.S.; Kurley, S.J.; Lee, E.J.; Woodruff, T.K. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res. 2005, 65, 7968–7975.
8. Ogawa, K.; Funaba, M.; Chen, Y.; Tsujimoto, M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J. Immunol. 2006, 177, 6787–6794.
9. Green, J.B.; New, H.V.; Smith, J.C. Responses of embryonic Xenopus cells to activin and FGF are separated by multiple dose thresholds and correspond to distinct axes of the mesoderm. Cell 1992, 71, 731–739.
10. Katz, L.H.; Li, Y.; Chen, J.-S.; Muñoz, N.M.; Majumdar, A.; Chen, J.; Mishra, L. Targeting TGF-β signaling in cancer. Expert Opin. Ther. Targets 2013, 17, 743–760.
11. Muttukrishna, S.; Tannetta, D.; Groome, N.; Sargent, I. Activin and follistatin in female reproduction. Mol. Cell. Endocrinol. 2004, 225, 45–56.
12. Meulmeester, E.; ten Dijke, P. The dynamic roles of TGF-β in cancer. J. Pathol. 2010, 223, 206–219.
13. Vale, W.; Rivier, C.; Hsueh, A.; Campen, C.; Meunier, H.; Bicsak, T.; Vaughan, J.; Corrigan, A.; Bardin, W.; Sawchenko, P. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog. Horm. Res. 1988, 44, 1–34.
14. Sheen, Y.Y.; Kim, M.-J.; Park, S.-A.; Park, S.-Y.; Nam, J.-S. Targeting the transforming growth factor-β signaling in cancer therapy. Biomol. Ther. 2013, 21, 323–331.
15. Barton, D.E.; Yang-Feng, T.L.; Mason, A.J.; Seeburg, P.H.; Francke, U. Mapping of genes for inhibin subunits α, β-A, and β-B on human and mouse chromosomes and studies of jsd mice. Genomics 1989, 5, 91–99.
16. Munger, J.S.; Harpel, J.G.; Gleizes, P.-E.; Mazzieri, R.; Nunes, I.; Rifkin, D.B. Latent transforming growth factor-β: Structural features and mechanisms of activation. Kidney Int. 2007, 51, 1376–1382.
17. Hyytiäinen, M.; Penttinen, C.; Keski-Oja, J. Latent TGF-β binding proteins: Extracellular matrix association and roles in TGF-β activation. Crit. Rev. Clin. Lab. Sci. 2004, 41, 233–264.
18. Chang, H.; Brown, C.W.; Matzuk, M.M. Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr. Rev. 2002, 23, 787–823.
19. Attisano, L.; Carcamo, J.; Ventura, F.; Weis, F.M.B.; Massagué, J.; Wrana, J.L. Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75, 1–10.
20. Lin, H.Y.; Wang, X.-F.; Ng-Eaton, E.; Weinberg, R.A.; Lodish, H.F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992, 68, 775–785.
21. De Caestecker, M. The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev. 2004, 15, 1–11.
22. Franzen, P.; Heldin, C.-H.; Miyazono, K. The GS domain of the transforming growth factor-β type I receptor is important in signal transduction. Biochem. Biophys. Res. Commun. 1995, 207, 682–689.
23. Wieser, R.; Wrana, J.L.; Massagué, J. GS domain mutations that constitutively activate TβR-1, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995, 14, 2199–2208.
24. Ten Dijke, P.; Yamashita, H.; Ichijo, H.; Franzen, P.; Laiho, M.; Miyazono, K.; Heldin, C.-H. Characterization of type I receptors for transforming growth factor-β and activin. Science 1994, 264, 101–104.
25. Carcamo, J.; Weis, F.M.; Ventura, F.; Wieser, R.; Wrana, J.L.; Attisano, L.; Massagué, J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol. Cell. Biol. 1994, 14, 3810–3821.
26. Gurdon, J.B.; Harger, P.; Mitchell, A.; Lemaire, P. Activin signalling and response to a morphogen gradient. Nature 1994, 371, 487–492.
27. Hashimoto, O.; Yamato, K.; Koseki, T.; Ohguchi, M.; Ishisaki, A.; Shoji, H.; Nakamura, T.; Hayashi, Y.; Sugino, H.; Nishihara, T. The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. Cell. Signal. 1998, 10, 743–749.
28. Symes, K.; Yordán, C.; Mercola, M. Morphological differences in Xenopus embryonic mesodermal cells are specified as an early response to distinct threshold concentrations of activin. Development 1994, 120, 2339–2346.
29. McDowell, N.; Zorn, A.M.; Crease, D.J.; Gurdon, J.B. Activin has direct long-range signalling activity and can form a concentration gradient by diffusion. Curr. Biol. 1997, 7, 671–681.
30. Heldin, C.-H.; Landström, M.; Moustakas, A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 2009, 21, 166–176.
31. McDowell, N.; Gurdon, J.B.; Grainger, D.J. Formation of a functional morphogen gradient by a passive process in tissue from the early Xenopus embryo. Int. J. Dev. Biol. 2001, 45, 199–207.
32. Stankic, M.; Pavlovic, S.; Chin, Y.; Brogi, E.; Padua, D.; Norton, L.; Massagué, J.; Benezra, R. TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep. 2013, 5, 1228–1242.
33. Di, X.; Andrews, D.M.K.; Tucker, C.J.; Yu, L.; Moore, A.B.; Zheng, X.; Castro, L.; Hermon, T.; Xiao, H.; Dixon, D. A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells. Exp. Mol. Med. 2012, 44, 281.
34. Frigon, N.L., Jr.; Shao, L.-E.; Young, A.L.; Maderazo, L.; Yu, J. Regulation of globin gene expression in human K562 cells by recombinant Activin A. Blood 1992, 3, 765–772.
35. Gressner, O.A. Intracrine signaling mechanisms of activin A and TGF-β. Vitam Horm. 2011, 85, 59–77.
36. James, D.; Levine, A.J.; Besser, D.; Hemmati-Brivanlou, A. TGFβ/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005, 132, 1273–1282.
37. Xu, R.-H.; Sampsell-Barron, T.L.; Gu, F.; Root, S.; Peck, R.M.; Pan, G.; Yu, J.; Antosiewicz-Bourget, J.; Tian, S.; Stewart, R.; et al. NANOG is a direct target of TGFβ/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008, 3, 196–206.
38. Wrana, J.L. Signaling by the TGFβ Superfamily. Cold Spring Harb. Perspect. Biol. 2013, 5, a011197–a011197.
39. Beyer, T.A.; Weiss, A.; Khomchuk, Y.; Huang, K.; Ogunjimi, A.A.; Varelas, X.; Wrana, J.L. Switch enhancers interpret TGF-β and hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 2013, 5, 1611–1624.
40. Itoh, F.; Watabe, T.; Miyazono, K. Seminars in cell & developmental biology. Semin. Cell Dev. Biol. 2014, 32, 98–106.
41. Jones, R.L.; Findlay, J.K.; Farnworth, P.G.; Robertson, D.M.; Wallace, E.; Salamonsen, L.A. Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: Potential interactions during decidualization and trophoblast invasion. Endocrinology 2006, 147, 724–732.
42. Hedger, M.P.; Winnall, W.R. Regulation of activin and inhibin in the adult testis and the evidence for functional roles in spermatogenesis and immunoregulation. Mol. Cell. Endocrinol. 2012, 359, 30–42.
43. Keutmann, H.T.; Schneyer, A.L.; Sidis, Y. The role of follistatin domains in follistatin biological action. Mol. Endocrinol.2004, 18, 228–240.
44. Osteen, K.G.; Igarashi, T.M.; Bruner-Tran, K.L. Progesterone action in the human endometrium: Induction of a unique tissue environment which limits matrix metalloproteinase (MMP) expression. Front. Biosci. 2003, 8, d78–d86.
45. De Winter, J.P.; ten Dijke, P.; de Vries, C.J.; van Achterberg, T.A.; Sugino, H.; de Waele, P.; Huylebroeck, D.; Verschueren, K.; van den Eijnden-van Raaij, A.J.M. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Mol. Cell. Endocrinol. 1996, 116, 105–114.
46. Canigga, I.; Lye, S.J.; Cross, J.C. Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology1997, 138, 3976–3986.
47. Ogawa, K.; Funaba, M.; Mathews, L.S.; Mizutani, T. Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J. Immunol. 2000, 165, 2997–3003.
48. Zhao, J.; Taverne, M.A.M.; van der Weijden, G.C.; Bevers, M.M.; van den Hurk, R. Effect of activin A on in vitro development of rat preantral follicles and localization of activin A and activin receptor II. Biol. Reprod. 2001, 65, 967–977.
49. Schneyer, A.L.; Wang, Q.; Sidis, Y.; Sluss, P.M. Differential distribution of follistatin isoforms: Application of a new FS315-specific immunoassay. J. Clin. Endocrinol. Metab. 2004, 89, 5067–5075.
50. Duggal, G.; Heindryckx, B.; Warrier, S.; O’Leary, T.; van der Jeught, M.; Lierman, S.; Vossaert, L.; Deroo, T.; Deforce, D.; Chuva de Sousa Lopes, S.M.; et al. Influence of activin a supplementation during human embryonic stem cell derivation on germ cell differentiation potential. Stem Cells Dev. 2013, 22, 3141–3155.
51. Thompson, T.B.; Lerch, T.F.; Cook, R.W.; Woodruff, T.K.; Jardetzky, T.S. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell2005, 9, 535–543.
52. Toivonen, S.; Lundin, K.; Balboa, D.; Ustinov, J.; Tamminen, K.; Palgi, J.; Trokovic, R.; Tuuri, T.; Otonkoski, T. Activin A and Wnt-dependent specification of human definitive endoderm cells. Exp. Cell Res. 2013, 319, 2535–2544.
53. Hashimoto, O.; Nakamura, T.; Shoji, H.; Shimasaki, S.; Hayashi, Y.; Sugino, H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J. Biol. Chem. 1997, 272, 13835–13842.
54. Nakamura, T.; Takio, K.; Eto, Y.; Shibai, H.; Titani, K.; Sugino, H. Activin-binding protein from rat ovary is follistatin. Science1990, 247, 836–838.
55. Evseenko, D.; Zhu, Y.; Schenke-Layland, K.; Kuo, J.; Latour, B.; Ge, S.; Scholes, J.; Dravid, G.; Li, X.; MacLellan, W.R.; et al. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc. Natl. Acad. Sci. USA2010, 107, 13742–13747.
56. Munz, B.; Tretter, Y.P.; Hertel, M.; Engelhardt, F.; Alzheimer, C.; Werner, S. The roles of activins in repair processes of the skin and the brain. Mol. Cell. Endocrinol. 2001, 180, 169–177.
57. Robertson, D.M.; de Vos, F.L.; Foulds, L.M.; McLachlan, R.I.; Burger, H.G.; Morgan, F.J.; Hearn, M.T.W.; de Kretser, D.M. Isolation of a 31 kDa form of inhibin from bovine follicular fluid. Mol. Cell. Endocrinol. 1986, 44, 271–277.
58. Jaźwińska, A.; Badakov, R.; Keating, M.T. Activin-βA signaling is required for zebrafish fin regeneration. Curr. Biol. 2007, 17, 1390–1395.
59. Lewis, K.A.; Gray, P.C.; Blount, A.L.; MacConell, L.A.; Wiater, E.; Bilezikjian, L.M.; Vale, W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature2000, 404, 411–414.
60. Miyazono, K. Positive and regative regulation of TGF-β signaling. J. Cell Sci. 2000, 113, 1101–1109.
61. Hübner, G.; Hu, Q.; Smola, H.; Werner, S. Strong induction of activin expression after injury suggests an important role of activin in wound repair. Dev. Biol. 1996, 173, 490–498.
62. Acloque, H.; Adams, M.S.; Fishwick, K.; Bronner-Fraser, M.; Nieto, M.A. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J. Clin. Invest. 2009, 119, 1438–1449.
63. Green, J.B.; Howes, G.; Symes, K.; Cooke, J.; Smith, J.C. The biological effects of XTC-MIF: Quantitative comparison with Xenopus bFGF. Development 1990, 108, 173–183.
64. Yndestad, A.; Ueland, T.; Øie, E.; Florholmen, G.; Halvorsen, B.; Attramadal, H.; Simonsen, S.; Frøland, S.S.; Gullestad, L.; Christensen, G.; et al. Elevated levels of activin A in heart failure: Potential role in myocardial remodeling. Circulation 2004, 109, 1379–1385.
65. Tuxhorn, J.A.; Ayala, G.E.; Smith, M.J.; Smith, V.C.; Dang, T.D.; Rowley, D.R. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002, 8, 2912–2923.
66. Sulyok, S.; Wankell, M.; Alzheimer, C.; Werner, S. Activin: An important regulator of wound repair, fibrosis, and neuroprotection. Mol. Cell. Endocrinol. 2004, 225, 127–132.
67. Roberts, A.B.; Sporn, M.B. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol. Reprod. Dev.1992, 32, 91–98.
68. Reis, F.M.; Cobellis, L.; Tameirão, L.C.; Anania, G.; Luisi, S.; Silva, I.S.B.; Gioffrè, W.; di Blasio, A.M.; Petraglia, F. Serum and tissue expression of activin a in postmenopausal women with breast cancer. J. Clin. Endocrinol. Metab. 2002, 87, 2277–2282.
69. Hofland, J.; van Weerden, W.M.; Steenbergen, J.; Dits, N.F.J.; Jenster, G.; de Jong, F.H. Activin A stimulates AKR1C3 expression and growth in human prostate cancer. Endocrinology 2012, 153, 5726–5734.
70. Thakur, N.; Gudey, S.K.; Marcusson, A.; Fu, J.Y.; Bergh, A.; Heldin, C.-H.; Landström, M. TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle 2014, 13, 2400–2414.
71. Liu, Q.Y.; Niranjan, B.; Gomes, P.; Gomm, J.J.; Davies, D.; Coombes, R.C.; Buluwela, L. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res. 1996, 56, 1155–1163.
72. Xiao, L.; Yuan, X.; Sharkis, S.J. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells 2006, 24, 1476–1486.
73. Kowanetz, M.; Valcourt, U.; Bergström, R.; Heldin, C.-H.; Moustakas, A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein. Mol. Cell. Biol. 2004, 24, 4241–4254.
74. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265–273.
75. Valcourt, U.; Kowanetz, M.; Niimi, H.; Heldin, C.-H.; Moustakas, A. TGFβ and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 2005, 16, 1987–2002.
76. Le Bras, G.F.; Taubenslag, K.J.; Andl, C.D. The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell Adh. Migr. 2012, 6, 365–373.
77. Thiery, J.P.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871–890.
78. Friedl, P.; Gilmour, D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2009, 10, 1–13
79. Chapnick, D.A.; Liu, X. Leader cell positioning drives wound-directed collective migration in TGFβ-stimulated epithelial sheets. Mol. Biol. Cell2014, 25, 1586–1593
80. Le Bras, G.F.; Taylor, C.; Koumangoye, R.B.; Revetta, F.; Loomans, H.A.; Andl, C.D. TGFβ loss activates ADAMTS-1-mediated EGF-dependent invasion in a model of esophageal cell invasion. Exp. Cell Res. 2014, 330, 29–42
81. Matise, L.A.; Palmer, T.D.; Ashby, W.J.; Nashabi, A.; Chytil, A.; Aakre, M.; Pickup, M.W.; Gorska, A.E.; Zijlstra, A.; Moses, H.L. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk. Breast Cancer Res. 2012, 14, R98
82. Fink, S.P.; Mikkola, D.; Willson, J.K.V.; Markowitz, S. TGF-β-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene2003, 22, 1317–1323
83. Jeruss, J.S.; Sturgis, C.D.; Rademaker, A.W.; Woodruff, T.K. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 2003, 63, 3783–3790
84. Togashi, Y.; Sakamoto, H.; Hayashi, H.; Terashima, M.; de Velasco, M.A.; Fujita, Y.; Kodera, Y.; Sakai, K.; Tomida, S.; Kitano, M.; et al. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol. Cancer2014, 13, 1–15
85. Kelner, N.; Rodrigues, P.C.; Bufalino, A.; Fonseca, F.; dos Santos-Silva, A.R.; Miguel, M.C.C.; Pinto, C.A.L.; Leme, A.F.P.; Graner, E.; Salo, T.; et al. Activin A immunoexpression as predictor of occult lymph node metastasis and overall survival in oral tongue squamous cell carcinoma. Head Neck2014, doi:10.1002/hed.23627
86. Seder, C.W.; Hartojo, W.; Lin, L.; Silvers, A.L.; Wang, Z.; Thomas, D.G.; Giordano, T.J.; Chen, G.; Chang, A.C.; Orringer, M.B.; et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia2009, 11, 388–396
87. Matzuk, M.M.; Kumar, T.R.; Vassalli, A.; Bickenbach, J.R.; Roop, D.R.; Jaenisch, R.; Bradley, A. Functional analysis of activins during mammalian development. Nature1995, 374, 354–356
88. Sang, Q.A.; Bodden, M.K.; Windsor, L.J. Activation of human progelatinase A by collagenase and matrilysin: Activation of procollagenase by matrilysin. J. Protein Chem. 1996, 15, 243–253
89. Yoshinaga, K.; Mimori, K.; Inoue, H.; Kamohara, Y.; Yamashita, K.; Tanaka, F.; Mori, M. Activin A enhances MMP-7 activity via the transcription factor AP-1 in an esophageal squamous cell carcinoma cell line. Int. J. Oncol. 2008, 33, 453–459
90. Brown, C.W.; Houston-Hawkins, D.E.; Woodruff, T.K.; Matzuk, M.M. Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat. Genet. 2000, 25, 453–457
91. Suyama, K.; Shapiro, I.; Guttman, M.; Hazan, R.B. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell2002, 2, 301–314
92. Yoshinaga, K.; Inoue, H.; Utsunomiya, T.; Sonoda, H.; Masuda, T.; Mimori, K.; anaka, Y.; Mori, M. N-Cadherin is regulated by Activin A and associated with tumor aggressiveness in esophageal carcinoma. Clin. Cancer Res. 2004, 10, 5702–5707.
93. Cufí, S.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Martin-Castillo, B.; Joven, J.; Menendez, J.A. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. Cell Cycle2010, 9, 4461–4468
94. Miyazono, K. Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B2009, 85, 314–323
95. Wang, Q.; Tabatabaei, S.; Planz, B.; Lin, C.W.; Sluss, P.M. Identification of an activin-follistatin growth modulatory system in the human prostate: Secretion and biological activity in primary cultures of prostatic epithelial cells. J. Urol. 1999, 161, 1378–1384
96. Lippitz, B.E. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. 2013, 14, e218–e228
97. Guo, Y.; Kyprianou, N. Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 1998, 9, 185–193
98. Krstic, J.; Santibanez, J.F. Transforming growth factor-β and matrix metalloproteinases: Functional interactions in tumor stroma-infiltrating myeloid cells. Sci. World J.2014, Article ID 521754
99. Barbara, N.P.; Wrana, J.L.; Letarte, M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J. Biol. Chem. 1999, 274, 584–594.
100. Breen, M.J.; Moran, D.M.; Liu, W.; Huang, X.; Vary, C.P.H.; Bergan, R.C. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. PLOS ONE2013, 8, e72407.
101. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell2000, 100, 57–70.
102. Ottley, E.; Gold, E. Insensitivity to the growth inhibitory effects of activin A: An acquired capability in prostate cancer progression. Cytokine Growth Factor Rev. 2012, 23, 119–125.
103. Huber, S.; Stahl, F.R.; Schrader, J.; Luth, S.; Presser, K.; Carambia, A.; Flavell, R.A.; Werner, S.; Blessing, M.; Herkel, J.; et al. Activin A promotes the TGF-β-induced conversion of CD4+CD25- cells into Foxp3+ induced regulatory T cells. J. Immunol. 2009, 182, 4633–4640.
104. Chang, K.-P.; Kao, H.-K.; Liang, Y.; Cheng, M.-H.; Chang, Y.-L.; Liu, S.-C.; Lin, Y.-C.; Ko, T.-Y.; Lee, Y.-S.; Tsai, C.-L.; et al. Overexpression of activin A in oral squamous cell carcinoma: Association with poor prognosis and tumor progression. Ann. Surg. Oncol. 2010, 17, 1945–1956.
105. Fu, S.; Zhang, N.; Yopp, A.C.; Chen, D.; Mao, M.; Chen, D.; Zhang, H.; Ding, Y.; Bromberg, J.S. TGF-β induces Foxp3 + T-regulatory cells from CD4 + CD25—Precursors. Am. J. Transpl. 2004, 4, 1614–1627.
106. Ogawa, K.; Funaba, M. Activin in humoral immune responses. Vitam Horm. 2011, 85, 235–253.
107. Yamashita, N.; Nakajima, T.; Takahashi, H.; Kaneoka, H.; Mizushima, Y.; Sakane, T. Effects of activin A on IgE synthesis and cytokine production by human peripheral mononuclear cells. Clin. Exp. Immunol. 2006, 94, 214–219.
108. Zipori, D.; Barda-Saad, M. Role of activin A in negative regulation of normal and tumor B lymphocytes. J. Leukoc. Biol. 2001, 69, 867–873.
109. Ogawa, K.; Funaba, M.; Tsujimoto, M. A dual role of activin A in regulating immunoglobulin production of B cells. J. Leukoc. Biol. 2008, 83, 1451–1458
110. Steller, M.D.; Shaw, T.J.; Vanderhyden, B.C.; Ethier, J.-F. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol. Cancer Res. 2005, 3, 50–61.
111. Lebman, D.A.; Edmiston, J.S. The role of TGF-β in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1999, 1297–1304.
112. Caver, T.E.; O’Sullivan, F.X.; Gold, L.I.; Gresham, H.D. Intracellular demonstration of active TGFβ1 in B cells and plasma cells of autoimmune mice: IgG-bound TGFβ1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J. Clin. Invest. 1996, 98, 2496–2506.
113. Funaba, M.; Ikeda, T.; Ogawa, K.; Murakami, M.; Abe, M. Role of activin A in murine mast cells: Modulation of cell growth, differentiation, and migration. J. Leukoc. Biol.2003, 73, 793–801.
114. Robson, N.C.; Wei, H.; McAlpine, T.; Kirkpatrick, N.; Cebon, J.; Maraskovsky, E. Activin A attenuates several human natural killer cell functions. Blood 2009, 113, 3218–3225.
115. Seeger, P.; Bosisio, D.; Parolini, S.; Badolato, R.; Gismondi, A.; Santoni, A.; Sozzani, S. Activin A as a mediator of NK-dendritic cell functional interactions. J. Immunol. 2014, 192, 1241–1248.
116. Mu, Y.; Sundar, R.; Thakur, N.; Ekman, M.; Gudey, S.K.; Yakymovych, M.; Hermansson, A.; Dimitriou, H.; Bengoechea-Alonso, M.T.; Ericsson, J.; et al. TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Comms. 2011, 2, 330.
117. Sierra-Filardi, E.; Puig-Kröger, A.; Blanco, F.J.; Nieto, C.; Bragado, R.; Palomero, M.I.; Bernabéu, C.; Vega, M.A.; Corbí, A.L. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 2011, 117, 5092–5101.
118. Hao, N.-B.; Lü, M.-H.; Fan, Y.-H.; Cao, Y.-L.; Zhang, Z.-R.; Yang, S.-M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012, 1–11.
119. Condeelis, J.; Pollard, J.W. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124, 263–266.
120. Cozzolino, F.; Torica, M.; Lucibello, M.; Morbidelli, L.; Ziche, M.; Platt, J.; Fabiani, S.; Brett, J.; Stern, D. Interferon-α and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J. Clin. Invest. 1993, 91, 2504–2512.
121. Barron, D.A.; Rowley, D.R. The reactive stroma microenvironment and prostate cancer progression. Endocr. Relat. Cancer 2012, 19, R187–R204.
122. Abe, M.; Shintani, Y.; Eto, Y.; Harada, K.; Fujinaka, Y.; Kosaka, M.; Matsumoto, T. Interleukin-1β enhances and interferon-γ suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts. Clin. Exp. Immunol. 2001, 126, 64–68.
123. Cho, S.H.; Yao, Z.; Wang, S.-W.; Alban, R.F.; Barbers, R.G.; French, S.W.; Oh, C.K. Regulation of activin A expression in mast cells and asthma: Its effect on the proliferation of human airway smooth muscle cells. J. Immunol. 2003, 170, 4045–4052.
124. Karagiannidis, C.; Hense, G.; Martin, C.; Epstein, M.; Rückert, B.; Mantel, P.-Y.; Menz, G.; Uhlig, S.; Blaser, K.; Schmidt-Weber, C.B. Activin A is an acute allergen-responsive cytokine and provides a link to TGF-β-mediated airway remodeling in asthma. J. Allergy Clin. Immunol. 2006, 117, 111–118.
125. Massagué, J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630.
126. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6, 392–401.
127. Sobral, L.M.; Bufalino, A.; Lopes, M.A.; Graner, E.; Salo, T.; Coletta, R.D. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol. 2011, 47, 840–846.
128. Bhowmick, N.A.; Chytil, A.; Plieth, D.; Gorska, A.E.; Dumont, N.; Shappell, S.; Washington, M.K.; Neilson, E.G.; Moses, H.L. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science2004, 303, 848–851.
129. Cheng, N.; Bhowmick, N.A.; Chytil, A.; Gorksa, A.E.; Brown, K.A.; Muraoka, R.; Arteaga, C.L.; Neilson, E.G.; Hayward, S.W.; Moses, H.L. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks. Oncogene2005, 24, 5053–5068.
130. McPherson, S.J.; Mellor, S.L.; Wang, H.; Evans, L.W.; Groome, N.P.; Risbridger, G.P. Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology1999, 140, 5303–5309.
131. Lin, S.; Ying, S.Y. Differentially expressed genes in activin-induced apoptotic LNCaP cells. Biochem. Biophys. Res. Commun. 1999, 257, 187–192.
132. Feinberg, M.W.; Jain, M.K.; Werner, F.; Sibinga, N.E.S.; Wiesel, P.; Wang, H.; Topper, J.N.; Perrella, M.A.; Lee, M.E. Transforming growth factor-β1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J. Biol. Chem. 2000, 275, 25766–25773.
133. Loomans, H.A.; Le Bras, G.F.; Zijlstra, A.; Andl, C.D. Vanderbilt University Medical Center, Nashville, TN, USA, Unpublished data, 2014.
134. Tuxhorn, J.A.; McAlhany, S.J.; Yang, F.; Dang, T.D.; Rowley, D.R. Inhibition of transforming growth factor-β decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002, 62, 6021–6025.
135. Joyce, J.A.; Pollard, J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer2009, 9, 239–252.
136. Zhou, B.; Chen, W.-L.; Wang, Y.-Y.; Lin, Z.-Y.; Zhang, D.-M.; Fan, S.; Li, J.-S. A role for cancer-associated fibroblasts in inducing the epithelial-to-mesenchymal transition in human tongue squamous cell carcinoma. J. Oral Pathol. Med. 2014, 43, 585–592.
137. Kellermann, M.G.; Sobral, L.M.; da Silva, S.D.; Zecchin, K.G.; Graner, E.; Lopes, M.A.; Nishimoto, I.; Kowalski, L.P.; Coletta, R.D. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology2007, 51, 849–853.
138. Räsänen, K.; Vaheri, A. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 2010, 316, 2713–2722.
139. Kaneda, H.; Arao, T.; Matsumoto, K.; de Velasco, M.A.; Tamura, D.; Aomatsu, K.; Kudo, K.; Sakai, K.; Nagai, T.; Fujita, Y.; et al. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. Br. J. Cancer2011, 105, 1210–1217.
140. McCarthy, S.A.; Bicknell, R. Inhibition of vascular endothelial cell growth by activin-A. J. Biol. Chem. 1993, 268, 23066–23071.
141. Breit, S.; Ashman, K.; Wilting, J.; Rossler, J.; Hatzi, E.; Fotsis, T.; Schweigerer, L. Oncogene in human neuroblastoma cells: Down-regulation of an angiogenesis inhibitor identified as Activin A. Cancer Res. 2000, 60, 4595–4601.
142. Krneta, J.; Kroll, J.; Aleves, F.; Prahst, C.; Sananbenesi, F.; Dullin, C.; Kimmina, S.; Phillips, D.J.; Augustin, H.G. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res. 2006, 66, 5686–5695.
143. Panopoulou, E.; Murphy, C.; Rasmussen, H.; Bagli, E.; Rofstad, E.K.; Fotsis, T. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res. 2005, 65, 1877–1886.
144. Nold-Petry, C.A.; Rudloff, I.; Baumer, Y.; Ruvo, M.; Marasco, D.; Botti, P.; Farkas, L.; Cho, S.X.; Zepp, J.A.; Azam, T.; et al. IL-32 promotes angiogenesis. J. Immunol. 2014, 192, 589–602.
145. Petersen, M.; Pardali, E.; van der Horst, G.; Cheung, H.; van den Hoogen, C.; van der Pluijm, G.; ten Dijke, P. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 2009, 29, 1351–1361.
146. Nakagawa, T.; Li, J.H.; Garcia, G.; Mu, W.; Piek, E.; Bottinger, E.P.; Chen, Y.; Zhu, H.J.; Kang, D.-H.; Schreiner, G.F.; et al. TGF-β induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int. 2004, 66, 605–613.
147. Guillot, N.; Kollins, D.; Badimon, J.J.; Schlondorff, D.; Hutter, R. Accelerated reendothelialization, increased neovascularization and erythrocyte extravasation after arterial injury in BAMBI−/− mice. PLOS ONE 2013, 8, e58550.
148. De Bock, K.; Georgiadou, M.; Carmeliet, P. Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 2013, 18, 634–647.
149. Goumans, M.-J.; Valdimarsdottir, G.; Itoh, S.; Rosendahl, A.; Sideras, P.; ten Dijke, P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 2002, 21, 1743–1753.
150. Park, S.; DiMaio, T.A.; Liu, W.; Wang, S.; Sorenson, C.M.; Sheibani, N. Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-β signaling pathways. J. Cell Sci. 2013, 126, 1392–1405.
151. Bao, Y.L.; Tsuchida, K.; Liu, B.; Kurisaki, A.; Matsuzaki, T.; Sugino, H. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways. J. Endocrinol.2005, 184, 493–504.